What one share of Insight Molecular Diagnostics holds
We are a pioneering diagnostics technology company. Our mission is to expand access to novel molecular diagnostic testing, most immediately in the transplanted organ rejection testing category.
Insight Molecular Diagnostics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.05 |
|---|---|
| Profit | −$1.46 |
| Capex (buildings and equipment) | $0.12 |
| Free cash flow | −$0.92 |
| Cash and investments | $0.54 |
| Book value | −$0.65 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2014 | — | −$5.48 | $0.01 | −$1.29 | — | −$1.18 |
| 2015 | — | −$8.32 | $0.48 | −$4.50 | — | $8.21 |
| 2016 | — | −$8.42 | $0.08 | −$5.75 | — | $6.86 |
| 2017 | — | −$12.83 | $0.06 | −$8.93 | — | $2.80 |
| 2018 | — | −$8.32 | $0.02 | −$6.17 | — | $1.68 |
| 2019 | — | −$8.74 | $0.36 | −$8.04 | — | $10.81 |
| 2020 | $0.37 | −$9.14 | $0.37 | −$8.31 | — | $9.69 |
| 2021 | $0.49 | −$14.42 | $0.51 | −$8.59 | — | $14.14 |
| 2022 | $0.17 | −$13.25 | $0.78 | −$9.01 | — | $5.78 |
| 2023 | $0.20 | −$3.75 | $0.04 | −$3.09 | — | $2.48 |
| 2024 | $0.14 | −$4.66 | $0.04 | −$1.62 | — | −$0.70 |
| 2025 | $0.13 | −$1.65 | $0.10 | −$0.83 | — | −$1.10 |
Common questions about Insight Molecular Diagnostics
How much does one share of Insight Molecular Diagnostics earn?
Over the last 12 months, Insight Molecular Diagnostics lost $1.46 for each share on $0.05 of sales.
Does Insight Molecular Diagnostics pay a dividend?
Insight Molecular Diagnostics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Insight Molecular Diagnostics’s book value per share?
Insight Molecular Diagnostics’s book value is negative (−$0.65 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Insight Molecular Diagnostics have?
Each share of Insight Molecular Diagnostics has $0.54 of cash and investments, as of June 30, 2026.
What is Insight Molecular Diagnostics’s free cash flow per share?
−$0.92 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Insight Molecular Diagnostics bought back shares?
Insight Molecular Diagnostics’s share count rose about 3249% from 2014 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.